Annexon Biosciences: Annexon Expands Vonaprument Phase 3 Program in Geographic Atrophy with Addition of Month 24 Dual Primary Endpoint Complementing Month 15 Primary Endpoint and Launch of Open-Label
Annexon, Inc. (Nasdaq: ANNX) said it added a Month 24 dual primary endpoint to its Phase 3 ARCHER II trial of vonaprument for geographic atrophy in dry AMD, alongside the existing Month 15 endpoint. It also launched an open-label extension for long-term safety and benefit. Month 15 DMC assessment is expected in Q4 2026, with Month 24 results in Q3 2027.
How this was made
The 30-second read
Why it matters
The company is modifying the pivotal endpoint structure by adding a Month 24 dual primary endpoint and initiating an open-label extension to gather longer-term safety and benefit data, with DMC assessment scheduled for Q4 2026.
Market read
This is a pivotal-trial design and follow-on study update that shifts the decision framework toward success at either Month 15 or Month 24, with a clear upcoming catalyst in Q4 2026.
What to watch
The release does not provide updated efficacy or safety results, so the market may still discount the change until Month 15 data; also, DMC recommendations could lead to continued trial duration rather than immediate success confirmation.
Background
Annexon is advancing vonaprument (formerly ANX007) for dry AMD with geographic atrophy (GA) in the Phase 3 ARCHER II trial.
Ticker impact
Annexon added a Month 24 dual primary endpoint to its Phase 3 ARCHER II vonaprument trial and launched an open-label extension for GA.
Near-term upside bias as the market may view the dual-primary strategy as improving binary outcomes, with continued volatility into the Q4 2026 Month 15 milestone.
The release is a concrete, time-bound clinical development update with explicit decision points (DMC assessment in Q4 2026, Month 24 thereafter) and a new OLE study, which can reframe expected trial success odds and label-readiness timelines.
Market effects
Reinforces a broader biotech trend toward dual-primary endpoint strategies and longer-term OLE follow-through in late-stage ophthalmology programs.
Limited direct regional spillover; primarily affects US small/mid-cap biotech sentiment and clinical-trial risk appetite.
May modestly influence global GA ophthalmology competitive positioning by highlighting regulatory momentum (Fast Track, EMA PRIME) and trial execution.
Counterpoint
Dual primary endpoints can also complicate interpretation and may not fully de-risk efficacy if both timepoints underperform or if effect sizes diverge.
Key entities
- companyAnnexon, Inc.
Nasdaq-listed biopharmaceutical company running the Phase 3 ARCHER II trial for vonaprument in GA.
- drugvonaprument
Intravitreal antigen-binding fragment targeting C1q to inhibit the classical complement pathway for GA.
- clinical_trialARCHER II
Global, double-masked Phase 3 sham-controlled trial with primary efficacy timepoints at Months 15 and 24.
- clinical_studyOpen-label extension (OLE)
Long-term safety and benefit study following completion of Month 24 in ARCHER II.
- oversightData Monitoring Committee (DMC)
Independent committee assessing the primary endpoint at Month 15 and potentially recommending whether to proceed to Month 24 analysis.
